Miederer, Matthias

An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma

Sahin, U., Oehm, P., Derhovanessian, E., Jabulowsky, R. A., Vormehr, M., Gold, M., Maurus, D., Schwarck-Kokarakis, D., Kuhn, A. N., Omokoko, T., et al. (2020) · Nature

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 1,052

Tumor therapy with targeted atomic nanogenerators.

McDevitt, M. R., Ma, D., Lai, L. T., Simon, J., Borchardt, P., Frank, R. K., Wu, K., Pellegrini, V., Curcio, M. J., Miederer, M., et al. (2001) · Science

Radiopharmaceutical Chemistry and ApplicationsAdvanced Energy Technologies and Civil Engineering Innovations

Cited by 501

Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications

Miederer, M., Scheinberg, D. A., & McDevitt, M. R. (2008) · Advanced Drug Delivery Reviews

Radiopharmaceutical Chemistry and ApplicationsAdvanced Energy Technologies and Civil Engineering Innovations

Cited by 210

Preclinical Evaluation of the α-Particle Generator Nuclide 225Ac for Somatostatin Receptor Radiotherapy of Neuroendocrine Tumors

Miederer, M., Henriksen, G., Alke, A., Mossbrugger, I., Quintanilla-Martinez, L., Senekowitsch-Schmidtke, R., & Essler, M. (2008) · Clinical Cancer Research

Neuroendocrine Tumor Research AdvancesRadiopharmaceutical Chemistry and Applications

Cited by 155

DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapy.

Graf, F., Fahrer, J., Maus, S., Morgenstern, A., Bruchertseifer, F., Venkatachalam, S., Fottner, C., Weber, M. M., Huelsenbeck, J., Schreckenberger, M., et al. (2014) · PLoS ONE

Radiopharmaceutical Chemistry and ApplicationsNeuroendocrine Tumor Research Advances

Cited by 143